- Cool Tool – A Complete System for Viral Vector and Recombinant Protein Production in HEK293 CellsPosted 44 mins ago
- Automated Collection and Analysis of Bioreactor Samples to Enable Quality by Design InitiativesPosted 23 hours ago
- Development of Animal-free Peptones for Mammalian and Microbial CulturePosted 1 week ago
- Cool Tool – Fluid Transfer Sets Specifically Designed for Sterile Transfer of Cell Therapy Based ProductsPosted 1 week ago
- Electroporation-based Transfection Demonstrates Consistent Antibody Quality and Glycosylation Patterns for Biotherapeutic Product DevelopmentPosted 1 month ago
- Cool Tool – Cell Culture Basics Virtual LabPosted 1 month ago
- Video – Bioprocessing pH Probe Selection and MaintenancePosted 1 month ago
- Cool Tool – Kits to Simplify and Standardize Your Immune Cell CulturesPosted 1 month ago
- Cool Tool – An Optimized, Chemically-Defined, Animal Component-Free Neural Basal MediumPosted 1 month ago
- Cool Tool – Lynx CDR Connectors to Improve Sterile Fluid Transfer in BiomanufacturingPosted 1 month ago
Takeda Brings Cell Based Influenza Vaccine Production to Japan with Baxter’s Assistance
Takeda Pharmaceutical Company (Japan) recently announced they have received a 23.9 billion yen subsidy from the Japanese government to develop the production capability for new influenza vaccines. Last year, Takeda and Baxter entered into a license agreement for Baxter’s proprietary Vero cell culture based influenza vaccine technology. Baxter is one of the few companies in the world with a cell culture produced influenza vaccine.
Takeda plans begin shipments of vaccine in 2014 and will initially develop a vaccine to immunize against H5N1 avian flu. Takeda is expected to build capacity to produce sufficient vaccine for at least 40 million people
Takeda will set up a new facility at its Hikari plant and use Baxter’s Vero cell production technology to produce vaccines faster than conventional methods that rely on chicken eggs. Takeda and other major Japanese drug makers pulled out of flu vaccine production in the mid-1990’s after a legal change made immunizations voluntary. The legal challenge reduced demand for the vaccine.
The Vero cell line is a continuous cell line and has been in use for decades to produce Polio vaccine in the United States. Thus, the Vero cell line has a history of safety and regulatory acceptance. Cell based influenza production using Vero or MDCK cells has been gaining acceptance in Europe and other parts of the world. However, an influenza vaccine using cell based production has not yet been approved by the United States Food and Drug Administration (FDA). Approximately 160 million doses of influenza vaccine are produced for the United States market each year. The Production of US influenza vaccines rely on traditional egg based production that is considered slower and more limited in scale than newer cell based technology.
For further reading, please see:
- Takeda Selected as Recipient of Government Subsidy for Developing Cell Culture-Based Influenza Vaccine – http://finchannel.com/news_flash/Pharmacy/93267_Takeda_Select_as_Recipient_of_Government_Subsidy_for_Developing_Cell_Culture-Based_Influenza_Vaccine/
- Takeda Press Release – http://www.takeda.com/press/article_42800.html
- Baxter Press Release – http://www.baxter.com/press_room/press_releases/2010/10_21_10-third_qtr_earnings.html